Amryt Pharma PLC New Distribution Agreement Signed (4150B)
January 10 2018 - 1:00AM
UK Regulatory
TIDMAMYT
RNS Number : 4150B
Amryt Pharma PLC
10 January 2018
10 January 2018
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
New Distribution Agreement Signed
Expanding Route to Market
Amryt, a biopharmaceutical company focused on rare and orphan
diseases, is pleased to announce that it has further expanded its
route to market for Lojuxta(R) (lomitapide), having signed an
exclusive distribution agreement covering Central and Eastern
Europe ("CEE") with GryNumber Health ("GryNumber"). GryNumber is
one of the leading healthcare consultancy and distribution
companies in the region, with many years of experience.
The agreement covers the distribution of Lojuxta across Austria,
Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia,
Lithuania, Poland, Slovakia and Slovenia. Lojuxta is a treatment
for the rare, life-threatening, genetic cholesterol disorder
Homozygous Familial Hypercholesterolemia ("HoFH") and Amryt
estimates that there are approximately 100 patients with HoFH in
these countries, with requests for access to Lojuxta made by
clinicians throughout the region.
Amryt has signed distribution contracts covering Saudi Arabia
and Switzerland recently as it continues to develop sales of
Lojuxta, having acquired exclusive marketing rights to the drug
across certain territories in December 2016.
Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma,
said:
"GryNumber Health has a well-established presence in, and
significant experience of, the healthcare markets in Central and
Eastern Europe and therefore is an ideal partner for us in the
region. We are delighted to have signed this exclusive distribution
agreement as we look to provide access to Lojuxta to patients
suffering from HoFH across our licensed territories."
Enquiries:
C/o KTZ Communications
Amryt Pharma plc (details below)
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital +44 (0) 20 7408 4090
Nomad and Joint Broker
Edward Mansfield, Mark
Percy
Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Irene
Bermont-Penn, Emma Pearson
About Amryt Pharma plc
(www.amrytpharma.com)
Amryt Pharma is a specialty biopharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
The Company holds an exclusive licence to sell Lojuxta
(lomitapide) for adults, across the European Economic Area, Middle
East and North Africa, Turkey and Israel. Lojuxta is used to treat
a rare life-threatening disease called Homozygous Familial
Hypercholesterolemia, which impairs the body's ability to remove
LDL cholesterol ("bad" cholesterol) from the blood. This typically
results in extremely high blood LDL cholesterol levels, leading to
aggressive and premature narrowing and blocking of arterial blood
vessels. If left untreated, heart attack or sudden death may occur
in childhood or early adulthood.
Amryt's lead drug candidate, AP101, is a potential treatment for
Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin
disorder affecting young children for which there is currently no
treatment. It is currently in Phase 3 clinical trials. The global
market opportunity for EB is estimated to be in excess of EUR 1.3
billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
About GryNumber Health
(www.grynumberhealth.com)
GryNumber Health is a healthcare consultancy and distribution
company dedicated to helping businesses become more effective and
successful while increasing their competitive edge in today's
constantly evolving market. While specialising in providing access
to small and medium size markets in Europe for Pharmaceutical and
Diagnostic companies, GryNumber Health creates new opportunities
for patients, healthcare professionals and businesses.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGREAXFNEDLPEFF
(END) Dow Jones Newswires
January 10, 2018 02:00 ET (07:00 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024